Icon

NINLARO (nda208462)- (EQ 2.3MG BASE,EQ 3MG BASE,EQ 4MG BASE)

IXAZOMIB CITRATE TAKEDA PHARMS USA
EQ 2.3MG BASE,EQ 3MG BASE,EQ 4MG BASE
Yes No
2029-Nov-20 2020-Nov-20
2022-Nov-20 None
None No
NINLARO is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
0 0 0
Total Other Developers 3
Drugs with Suitability No
EQ 2.3MG BASE ** ** - - -
EQ 3MG BASE ** ** - - -
EQ 4MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.